Clinical trial

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

BioMarin PharmaceuticalCompletedPhase 3Started Jul 1, 2011173 enrolledUnited States, Argentina, Brazil, Canada, Colombia, Denmark, France, Germany, Italy, Japan, Netherlands, Norway, Portugal, Qatar, Saudi Arabia, South Korea, Spain, Taiwan, Turkey (Türkiye), United KingdomNCT01415427

Abstract

This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

LSD

Keywords

Mucopolysaccharidosis IV type AMPS IV Type AMucopolysaccharidosis IVAMPS IVAMorquio A SyndromeLysosomal Storage DisorderN-acetylgalactosamine-6-sulfataseN-acetylgalactosamine-6-sulfate sulfatasegalactose-6-sulfataseGALNSenzyme replacement therapyERTMucopolysaccharidosis IV AMorquio A SyndromeMPS IVA

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

MFCC-DFT mapping of ligand recognition at the 5-HT<sub>2A</sub> receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.

Junior WSC, Bezerra KS, Matias EGC +2

Europe PMC2026

ArticleLSD

LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm.

Timmermann C, Spriggs MJ, Kaelen M +5

Europe PMC2018

ArticleLSD

Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.

Schindler EA, Harvey JA, Aloyo VJ

Europe PMC2013